I am encouraged that Botanix said that 50% of dermatologists they spoke with would try Sofdra as first line, and they plan on having a big sales force visiting those 4500 dermatologists.
Their sales and market penetration plan, looks very aggressive, and I don't know if Kaken have taken steps anything like what BOT are proposing.
Of interest, 85% of patients for the BOT trial said they felt an improvement, whereas only around 65% from qbrexa trial ( current best approved treatment ) said they felt improvement. The gravametric sweat reduction was similar at close to 70% for the two products. Price is 600 to 700 per month for qbrexa.
So while not 100%, according to the patients, 85% vs 65%, its a better product than the only FDA approved treatment currently available , and will be at a similar price.
- Forums
- ASX - By Stock
- Where will we be in 12 months time?
I am encouraged that Botanix said that 50% of dermatologists...
-
- There are more pages in this discussion • 61 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BOT (ASX) to my watchlist
|
|||||
Last
38.0¢ |
Change
0.010(2.70%) |
Mkt cap ! $687.8M |
Open | High | Low | Value | Volume |
37.0¢ | 38.0¢ | 36.5¢ | $1.324M | 3.541M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 4056 | 37.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
38.0¢ | 653729 | 17 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 4056 | 0.370 |
3 | 139768 | 0.365 |
7 | 205337 | 0.360 |
2 | 94461 | 0.355 |
4 | 439000 | 0.350 |
Price($) | Vol. | No. |
---|---|---|
0.380 | 649482 | 16 |
0.385 | 410186 | 6 |
0.390 | 352859 | 19 |
0.395 | 378120 | 10 |
0.400 | 866716 | 22 |
Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
Featured News
BOT (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online